Please assess the completion status of the following clinical trial:

Trial Title: Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of B-cell chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, including Waldenstrom's macroglobulinemia, as indicated by the following:~  * Massive or progressive splenomegaly and/or lymphadenopathy~ * Anemia (hemoglobin less than 11 g/dL) or thrombocytopenia (platelet count less than 100,000/mm\^3)~ * Weight loss of more than 10% within the past 6 months~ * Grade 2 or 3 fatigue~ * Fevers greater than 100.5º C or night sweats for more than 2 weeks with no evidence of infection~ * Progressive lymphocytosis with an increase of more than 50% over a 2-month period or anticipated doubling time of less than 6 months~* Received at least 1 prior therapy for CLL~* Performance status - ECOG (Eastern Cooperative Oncology Group) 0-2~* See Disease Characteristics~* WBC (white blood count) less than 200,000/mm\^3~* Bilirubin no greater than 1.5 times normal (unless due to Gilbert's disease or any of the conditions stated below)\*~* AST (aspartate aminotransferase) no greater than 2 times normal\*~* Creatinine no greater than 2.0 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other malignancy that would limit survival to less than 2 years~* No history of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) unless inactive for more than 2 years~* No psychiatric condition that would preclude compliance with treatment or giving informed consent~* No other concurrent chemotherapy~* No concurrent chronic corticosteroids~* No concurrent hormonal therapy except steroids for new adrenal failure or hormonal agents for nondisease-related conditions (e.g., insulin for diabetes)~* No concurrent dexamethasone or other corticosteroid-based antiemetics~* No concurrent radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive a loading dose of flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of unacceptable toxicity or disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).